Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine and Albumin for Refractory Ascites in Decompensated Cirrhosis
NCT04816240Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in decompensated cirrhosis comparing Midodrine + Albumin with Placebo + Albumin (2 arms). Primary endpoint: Survival free of transplant and TIPS at 6 months. Status: unknown.
02
Drugs
midodrine
03
Conditions
decompensated cirrhosis
Beyond the preview
Go deeper on NCT04816240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816240.